OBI Pharma announces OBI-3424 results from the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

Study finds OBI-3424 exerts profound in vivo efficacy and safety against patient-derived xenograft (PDX) models of T-cell acute lymphoblastic leukemia (T-ALL) expressing AKR1C3. Taipei, Taiwan, October 29, 2017 – OBI Pharma, Inc., a Taiwan biopharma company (TPEx: 4174), announced the results of a patient-derived xenograft (PDX) model study of OBI-3424 in T-cell acute lymphoblastic leukemia […]